Adalimumab - USA

Decision on IPR: Nov 02, 2018

AIA Review	Filing Date	Institution Date	Petitioner	US Patent	Respondent	Status
IPR2017-02105	09/14/2017	04/03/2018	Sandoz Inc.	9,090,689	AbbVie	Terminated - Settled
IPR2017-02106	09/14/2017	04/03/2018	Sandoz Inc.	9,067,992	AbbVie	Terminated - Settled

US 9,090,689 (AbbVie Biotechnology, Ltd; Exp: Jul 18, 2023)

1. A method of administering adalimumab for treatment of moderate to severe chronic plaque psoriasis, comprising filling adalimumab into vessels and subcutaneously administering 40 mg of said adalimumab to a patient having moderate to severe chronic plaque psoriasis every other week.

7. A method of preparing adalimumab for treating moderate to severe chronic plaque psoriasis, comprising filling adalimumab into vessels and providing said adalimumab for treatment, wherein said treatment comprises subcutaneously administering 40 mg of said adalimumab to a patient having moderate to severe chronic plaque psoriasis every other week.

US 9,067,992 (AbbVie Biotechnology, Ltd; Exp: Jul 18, 2023)

1. A method of treatment of moderate to severe active psoriatic arthritis in adult patients, wherein each said patient has .gtoreq.3 swollen and .gtoreq.3 tender joints prior to the treatment and has failed NSAID therapy, comprising subcutaneously administering to each said patient 40 mg of adalimumab every other week, wherein 23% of said patients achieve 70% reduction in American College of Rheumatology (ACR) score at week 24 of the treatment.